Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beale

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|August 19, 2004
Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literatureJ Vardy, K Engelhardt, K Cox, et al.
Emergency Medicine Journal : EMJ|January 21, 2003
Rapid sequence intubation in Scottish urban emergency departmentsC A Graham, D Beard, A J Oglesby, et al.
Patient Education and Counseling|February 5, 2022
The impact of COVID-19 on cancer patients, their carers and oncology health professionals: A qualitative studyP Butow, P E Havard, Z Butt, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupE Briasoulis, I Judson, N Pavlidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2006
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerR A Soo, L Z Wang, L S Tham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 30, 2019
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patientsM E S Smith-Uffen, S B Johnson, A J Martin, et al.
Gynecologic Oncology|October 9, 2021
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)R J Edmondson, R L O'Connell, S Banerjee, et al.
Gynecologic Oncology|February 20, 2021
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)M Friedlander, C Benson, R L O'Connell, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|August 19, 2004
Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literatureJ Vardy, K Engelhardt, K Cox, et al.
Emergency Medicine Journal : EMJ|January 21, 2003
Rapid sequence intubation in Scottish urban emergency departmentsC A Graham, D Beard, A J Oglesby, et al.
Patient Education and Counseling|February 5, 2022
The impact of COVID-19 on cancer patients, their carers and oncology health professionals: A qualitative studyP Butow, P E Havard, Z Butt, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupE Briasoulis, I Judson, N Pavlidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2006
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerR A Soo, L Z Wang, L S Tham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 30, 2019
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patientsM E S Smith-Uffen, S B Johnson, A J Martin, et al.
Gynecologic Oncology|October 9, 2021
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)R J Edmondson, R L O'Connell, S Banerjee, et al.
Gynecologic Oncology|February 20, 2021
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)M Friedlander, C Benson, R L O'Connell, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
Pageof 7